# EU-1-20-1483_public-assessment-report_20201127_20201127_menquadfi-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
17 September 2020
EMA/522942/2020
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
MenQuadfi
International non-proprietary name: meningococcal group A, C, W135 and Y
conjugate vaccine
Procedure No. EMEA/H/C/005084/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
Official address Domenico Scarlattilaan 6 . 1083 HS Amsterdam . The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union
Table of contents
1. Background information on the procedure
8
1.1. Submission of the dossier
8
1.2. Steps taken for the assessment of the product
9
2. Scientific discussion
11
2.1. Problem statement
11
2.1.1. Disease or condition
11
2.1.2. Epidemiology and prevention
11
2.1.3. Biologic features Aetiology
11
2.1.4. Clinical presentation, diagnosis and stage/prognosis
11
2.1.5. Management
12
2.2. Quality aspects
13
2.2.1. Introduction
13
2.2.2. Active Substance
13
2.2.3. Finished Medicinal Product.
18
2.2.4. Discussion on chemical, pharmaceutical and biological aspects
22
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
22
2.2.6. Recommendation(s) for future quality development
22
2.3. Non-clinical aspects.
23
2.3.1. Introduction
23
2.3.2. Pharmacology
23
2.3.3. Pharmacokinetics
25
2.3.4. Toxicology
25
2.3.5. Ecotoxicity/environmental risk assessment
27
2.3.6. Discussion on non-clinical aspects
27
2.3.7. Conclusion on the non-clinical aspects
27
2.4. Clinical aspects
27
2.4.1. Introduction
27
2.4.2. Pharmacokinetics
30
2.4.3. Pharmacodynamics
30
2.4.4. Discussion on clinical pharmacology.
30
2.4.5. Conclusions on clinical pharmacology
30
2.5. Clinical efficacy
30
2.5.1. Dose response studies and main clinical studies
31
2.5.2. Discussion on clinical efficacy
71
2.5.3. Conclusions on the clinical efficacy
78
2.6. Clinical safety
79
2.6.1. Discussion on clinical safety
95
2.6.2. Conclusions on the clinical safety
100
EMA/CHMP/452679/2020
Page 2/121
